Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index; 21 of the 126 sources its claims cite were checked for support.

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

Open access

Abstract

Inherited retinal diseases (IRDs) are a leading cause of blindness in industrialized countries, and gene therapy is quickly becoming a viable option to treat this group of diseases. Gene replacement using a viral vector has been successfully applied and advanced to commercial use for a rare group of diseases. This, and the advances in gene editing, are paving the way for the emergence of a new generation of therapies that use CRISPR–Cas9 to edit mutated genes in situ. These CRISPR-based agents can be delivered to the retina as transgenes in a viral vector, unpackaged transgenes or as proteins or messenger RNA using non-viral vectors. Although the eye is considered to be an immune-privileged organ, studies in animals, as well as evidence from clinics, have concluded that ocular gene therapies elicit an immune response that can under certain circumstances result in inflammation. In this review, we evaluate studies that have reported on pre-existing immunity, and discuss both innate and adaptive immune responses with a specific focus on immune responses to gene editing, both with non-viral and viral delivery in the ocular space. Lastly, we discuss approaches to prevent and manage the immune responses to ensure safe and efficient gene editing in the retina.

Overview

CoChat Summary

TL;DR

This narrative review examines pre-existing and post-treatment innate and adaptive immune responses to retinal gene therapy, covering viral vectors (AAV, lentivirus, adenovirus), non-viral delivery (naked DNA, lipoplexes, polymers, nanoparticles, VLPs), and CRISPR-Cas9 components. It argues that the eye's immune privilege is not absolute and surveys vector-oriented and immune-response-oriented strategies to prevent or manage these responses.

Key findings

  • Pre-existing immunity to Cas9 is common: in 125 healthy US adult blood donors (median age 43), anti-SaCas9 and anti-SpCas9 antibodies were found in 78% and 58% respectively; 78% had SaCas9-specific T-cells and 67% SpCas9-specific T-cells. A canine study found anti-SpCas9 antibodies in all 78 adult animals but not in 16 newborns.
  • Pre-existing anti-AAV seroprevalence is high and serotype-dependent: in 226 healthy donors, serum IgG prevalence was AAV2 72%, AAV1 67%, AAV9 47%, AAV6 46%, AAV5 40%, AAV8 38%; in 888 serum samples across 10 countries, AAV2 was highest and the novel variant AAVrh32.33 lowest.
  • Clinical ocular gene therapy trials report inflammation: in NCT00999609 (Phase 3), mild inflammation in 2 of 21 patients; in NCT02781480 (Phase 1/2), uveitis in 1/3 low-dose, 3/3 intermediate-dose and 2/3 high-dose patients; in an AMD Ad trial, 25% of 28 patients developed transient intraocular inflammation; in a retinoblastoma cohort, 5 of 8 patients developed ocular inflammation without measurable humoral or cellular response.
  • Non-viral vectors are not necessarily less immunogenic: chitosan induced inflammatory cell infiltration and retinal degeneration in rabbits, while gold nanoparticles reduced LPS-induced inflammation via the TLR4-NFκB pathway; VLP-mediated base editing reached >95% efficiency in fibroblasts, 53–55% in mouse CNS, 63% in liver, and 21% in RPE with visual rescue in rd12 mice.

Methods

  • Narrative review; no experimental data were generated or presented (stated explicitly in the Institutional Review Board, Data Availability, and Additional Information statements).
  • Synthesizes published human, non-human primate, canine, rodent and in vitro studies on pre-existing immunity, innate and adaptive responses to viral and non-viral ocular delivery, and immunosuppressive strategies.
  • No systematic search protocol, inclusion criteria, or quantitative synthesis is described.

Limitations

  • Stated by the paper: immune responses are "highly individualistic," making concrete conclusions from small patient cohorts difficult; mechanistic insights into how responses occur at cellular or molecular levels are missing; immunosuppressive regimens are rarely reported in animal studies and inadequately documented in human studies, and no systematic comparative studies of corticosteroids exist.
  • Evident from the text: as a narrative review without a described search strategy, selection of cited studies may be non-exhaustive; several cited findings rest on very small samples (e.g., 3 serum samples, 3 patients, 8 patients), and the review itself notes that long-term immune-response data after Cas9 delivery in patients are not yet available.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14091973

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic representation of immune responses to ocular gene therapy. Some components of viral and non-viral delivery methods present danger signals to the immune system. Exposure to these components prior to gene therapy can result in pre-existing immunity. Individuals without prior exposure can activate innate and adaptive mechanisms after receiving ocular gene therapy. Individuals with pre-existing immunity can generate neutralizing antibodies (NAbs) that eliminate the vector and further trigger innate and adaptive responses. Together, these responses can result in an adverse outcome of ocular gene therapy, such as clearance of transduced cells, inflammation and reduction in visual acuity.
Figure 1 Schematic representation of immune responses to ocular gene therapy. Some components of viral and non-viral delivery methods present danger signals to the immune system. Exposure to these components prior to gene therapy can result in pre-existing immunity. Individuals without prior exposure can activate innate and adaptive mechanisms after receiving ocular gene therapy. Individuals with pre-existing immunity can generate neutralizing antibodies (NAbs) that eliminate the vector and further trigger innate and adaptive responses. Together, these responses can result in an adverse outcome of ocular gene therapy, such as clearance of transduced cells, inflammation and reduction in visual acuity.CC BY · PubMed Central
Figure 2 Schematic representation of immunosuppressive strategies. Strategies to suppress or control immune responses to gene therapy can be broadly categorized as vector-oriented or immune-response-oriented strategies. Vector-oriented strategies focus on design and dose of the carrier and the elements packaged within. Novel carriers are being designed with immune-evading properties such as the next generation of viruses as well as non-viral carriers such as virus-like particles (VLPs) and nanoblades. A higher dose poses a higher risk of exposure to danger signals; hence, the dose needs to be optimized to achieve the highest therapeutic efficacy with the lowest dose possible. Cell-specific promoters are more specific and less immunogenic than ubiquitous promoters. An addition of a TLR9 inhibition sequence (Tlr9i), deletion of CpG-rich regions in the transgene cassette and masking of TLR9 binding epitopes on the capsid have been shown to reduce TLR9-mediated immune responses. Novel Cas9 orthologs, to which a prior exposure has not occurred, may be less immunogenic. Immune-response-oriented strategies focus on avoiding or reducing the immune responses. An immunosuppressive regimen consisting of corticosteroids can be provided as topical eye drops or ocular injections before and after the gene therapy. TLR9 inhibitors can be used to prevent the activation of dendritic cells, thereby preventing cellular immune responses. Enzymatic cleavage of pre-existing anti-vector antibodies can be achieved by using enzymes such as IdeS. Immune deviation can be achieved by prior exposure to antigens by injection into the anterior chamber or subretinal space.
Figure 2 Schematic representation of immunosuppressive strategies. Strategies to suppress or control immune responses to gene therapy can be broadly categorized as vector-oriented or immune-response-oriented strategies. Vector-oriented strategies focus on design and dose of the carrier and the elements packaged within. Novel carriers are being designed with immune-evading properties such as the next generation of viruses as well as non-viral carriers such as virus-like particles (VLPs) and nanoblades. A higher dose poses a higher risk of exposure to danger signals; hence, the dose needs to be optimized to achieve the highest therapeutic efficacy with the lowest dose possible. Cell-specific promoters are more specific and less immunogenic than ubiquitous promoters. An addition of a TLR9 inhibition sequence (Tlr9i), deletion of CpG-rich regions in the transgene cassette and masking of TLR9 binding epitopes on the capsid have been shown to reduce TLR9-mediated immune responses. Novel Cas9 orthologs, to which a prior exposure has not occurred, may be less immunogenic. Immune-response-oriented strategies focus on avoiding or reducing the immune responses. An immunosuppressive regimen consisting of corticosteroids can be provided as topical eye drops or ocular injections before and after the gene therapy. TLR9 inhibitors can be used to prevent the activation of dendritic cells, thereby preventing cellular immune responses. Enzymatic cleavage of pre-existing anti-vector antibodies can be achieved by using enzymes such as IdeS. Immune deviation can be achieved by prior exposure to antigens by injection into the anterior chamber or subretinal space.CC BY · PubMed Central

Verification

Claims the paper makes

16 Valid · 6 Not valid · 96 Not checked · 40 Own results and interpretations

73 more claims · 8 with their cited sources checked

Create a free account to see all 158 claims and to verify the 105 references still open.

See all claims — free account
  • It may state two separate claims as one. 72
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 115 references

Cited by

See all 56

Metadata

Authors
Ren, D., Fisson, S., Dalkara, D., & Ail, D.
Affiliations
Centre National de la Recherche Scientifique (FR)
Corresponding author
Ail, Divya
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-09-19
Volume
14
Issue
9
Pages
1973
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4296794285
Cited by
52
References
115
Citations by year
2026: 10 · 2025: 15 · 2024: 14 · 2023: 13
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • ERC Starting Grant (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • Institut National de la Santé et de la Recherche Médicale (INSERM) (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • Sorbonne Université (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • The Foundation Fighting Blindness (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • Agence National de Recherche (ANR) RHU Light4Deaf (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • *LabEx LIFESENSES (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
  • *IHU FOReSIGHT (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
retinal gene therapy, CRISPR/Cas9 genome editing, immune response, viral vectors, non-viral vectors, inherited retinal disease, ocular inflammation, immune privilege, innate immunity, adaptive immunity, pre-existing immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy. https://app.cochat.ai/papers/10.3390/pharmaceutics14091973
The paper
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022). Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14091973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.